Development of highly potent and selective oncogenic KRASG12D PROTAC degraders
As a key driver of tumorigenesis and cancer development, the KRASG12D mutation is ubiquitous existed in KRAS-associated malignancies, highlighting the urgent clinical need for effective KRASG12D targeting drugs. In this study, through rational design and multiple cell type-based antiproliferative ev...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2025-12-01
|
| Serier: | European Journal of Medicinal Chemistry Reports |
| Fag: | |
| Online adgang: | http://www.sciencedirect.com/science/article/pii/S2772417425000524 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
